ACROBiosystems Presents AI-Driven Protein Solutions at Cancer Research Conference
ACROBiosystems presented its AI protein engineering platform at the American Association for Cancer Research Annual Meeting in April 2026. The company's system, called Acro-AIx, addresses recurring obstacles in protein development: low expression rates, instability, and solubility problems that drive up costs and timelines.
The platform uses two specialized AI models trained on proprietary data. DeepExp predicts secretory expression levels for full-length proteins in mammalian cells with 0.95 accuracy. ProDeSol forecasts solubility in prokaryotic systems at 0.94 accuracy.
How the System Works
Acro-AIx integrates AI predictions with wet-lab testing in a closed loop. Engineers use the models to propose protein designs, test them in the lab, and feed results back into the system to refine future predictions.
The company's "AI Box" toolkit autonomously optimizes multiple protein properties at once-binding affinity, stability, and solubility. This approach has produced materials for cell and gene therapy, including a nuclease and two stable protein variants used in GMP manufacturing.
Beyond the AI Models
ACROBiosystems supports protein development across multiple stages. The company operates expression platforms for prokaryotic, eukaryotic, and cell-free systems. It runs high-throughput screening for molecular construction and bioactivity analysis. Quality control follows ISO 9001 and GMP standards.
The company also offers specialized services: site-specific fluorescent labeling, custom GMP-grade proteins, and a transmembrane protein research platform.
What This Means for Product Development
For product development teams, the approach reduces guesswork in early-stage protein design. Faster predictions mean fewer failed experiments. Thermally stable proteins lower manufacturing costs and improve scalability.
ACROBiosystems has built partnerships with Pfizer, Novartis, and Johnson & Johnson. The company operates R&D centers and production facilities across the United States, Switzerland, the United Kingdom, and Germany.
If you work in biopharmaceutical development, understanding how AI for Product Development applies to protein engineering can inform decisions about outsourcing or platform selection. AI for Science & Research is becoming a standard tool in the field.
Your membership also unlocks:
